Literature DB >> 2898289

Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.

E K Rowinsky1, R C Donehower, R J Jones, R W Tucker.   

Abstract

Taxol, a diterpenoid plant product that enhances the polymerization of tubulin, is currently entering clinical trials in the treatment of human leukemia. In order to develop an in vitro assay to predict tumor sensitivity to taxol, human leukemic cell lines were exposed to clinically achievable concentrations of taxol for relevant exposure periods. Changes in microtubules visualized by indirect immunofluorescence were compared to drug sensitivity measured by a clonogenic assay. Taxol produced either multiple mitotic asters in G2/M or microtubule bundling throughout the cell cycle. In cells that were relatively resistant to taxol, microtubule bundling was reversible while microtubule bundling in relatively sensitive cells persisted in the presence or absence of taxol. In contrast, aster formation was unrelated to cytotoxicity in any cell line. In the future, these microtubule effects may be useful in predicting the chemotherapeutic efficacy of taxol.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898289

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

1.  Synergistic cytotoxicity of human recombinant tumour necrosis factor alpha combined with microtubule effectors.

Authors:  J Baumgart; B Schlott; J Suehnel; W Vater; W Schulze; D Behnke
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Induction of paclitaxel resistance by the Kaposi's sarcoma-associated herpesvirus latent protein LANA2.

Authors:  C Muñoz-Fontela; L Marcos-Villar; F Hernandez; P Gallego; E Rodriguez; J Arroyo; S-J Gao; J Avila; C Rivas
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

3.  Molecular cloning and heterologous expression of the C-13 phenylpropanoid side chain-CoA acyltransferase that functions in Taxol biosynthesis.

Authors:  Kevin Walker; Shingo Fujisaki; Robert Long; Rodney Croteau
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

4.  Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression.

Authors:  Rui Wang; Ke Dong; Fang Lin; Xi Wang; Ping Gao; San-Hua Wei; Shi-Yin Cheng; Hui-Zhong Zhang
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

5.  Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat.

Authors:  S J Sollott; L Cheng; R R Pauly; G M Jenkins; R E Monticone; M Kuzuya; J P Froehlich; M T Crow; E G Lakatta; E K Rowinsky
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

6.  Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel.

Authors:  Y Fromes; P Gounon; R Veitia; M C Bissery; A Fellous
Journal:  J Protein Chem       Date:  1996-05

7.  Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.

Authors:  Maurie Markman; P Y Liu; James Moon; Bradley J Monk; Larry Copeland; Sharon Wilczynski; David Alberts
Journal:  Gynecol Oncol       Date:  2009-05-17       Impact factor: 5.482

8.  In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules.

Authors:  R D Christen; A P Jekunen; J A Jones; F Thiebaut; D R Shalinsky; S B Howell
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

9.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.

Authors:  M A Jordan; R J Toso; D Thrower; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

10.  Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; G Abel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.